International Journal of Radiation Oncology * Biology * Physics
Volume 53, Issue 2 , Pages 394-400 , 1 June 2002

Gemcitabine-induced radiation recall

  • Melenda D Jeter, M.D., M.P.H.

      Affiliations

    • Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA, USA
    • Melenda D. Jeter and Pasi A. Jänne contributed equally to this work.
    • ,
  • Pasi A Jänne, M.D., Ph.D.

      Affiliations

    • Department of Adult Oncology and Medicine, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, MA, USA
    • Melenda D. Jeter and Pasi A. Jänne contributed equally to this work.
    • ,
  • Sarah Brooks, B.A.

      Affiliations

    • Department of Adult Oncology and Medicine, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, MA, USA
    • ,
  • Harold J Burstein, M.D., Ph.D.

      Affiliations

    • Department of Adult Oncology and Medicine, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, MA, USA
    • ,
  • Patrick Wen, M.D.

      Affiliations

    • Department of Adult Oncology and Medicine, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, MA, USA
    • ,
  • Charles S Fuchs, M.D.

      Affiliations

    • Department of Adult Oncology and Medicine, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, MA, USA
    • ,
  • Jay S Loeffler, M.D.

      Affiliations

    • Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA
    • ,
  • Phillip M Devlin, M.D.

      Affiliations

    • Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, MA, USA
    • ,
  • Ravi Salgia, M.D., Ph.D.

      Affiliations

    • Corresponding Author InformationReprint requests to: Ravi Salgia, M.D., Ph.D., Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute D1234B, 44 Binney Street, Boston, MA 02115 USA. Tel: (617) 632-3468; Fax: (617) 632-4379
    • Department of Adult Oncology and Medicine, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, MA, USA

Received 1 November 2001 ,Revised 1 February 2002 ,Accepted 11 February 2002.

References 

  1. John M. Radiotherapy and chemotherapy. In:  Leibel S,  Phillips T editor. Textbook of radiation oncology. Philadelphia: W.B. Saunders; 1998;p. 69–89
  2. Schweitzer VG, Juillard GJ, Bajada CL, Parker RG. Radiation recall dermatitis and pneumonitis in a patient treated with paclitaxel. Cancer. 1995;76(6):1069–1072
  3. D’Angio G, Farber S, Maddock C. Potentiation of x-ray effects by actinomycin-D. Radiology. 1959;73:175–177
  4. Dunagin W. Dermatologic toxicity. In:  Parry M,  Yarbro J editor. Toxicity of chemotherapy. Orlando: Grune and Stratton Inc; 1984;p. 125–154
  5. Adrian RM, Hood AF, Skarin AT. Mucocutaneous reactions to antineoplastic agents. CA Cancer J Clin. 1980;30(3):143–157
  6. Burstein HJ. Side effects of chemotherapy. Case 1. Radiation recall dermatitis from gemcitabine. J Clin Oncol. 2000;18(3):693–694
  7. Castellano D, Hitt R, Cortes-Funes H, et al.  Side effects of chemotherapy. Case 2. Radiation recall reaction induced by gemcitabine. J Clin Oncol. 2000;18(3):695–696
  8. Lawrence TS, Eisbruch A, Shewach DS. Gemcitabine-mediated radiosensitization. Semin Oncol. 1997;24(2 Suppl. 7):S7—24–S7—28
  9. Lawrence TS, Eisbruch A, McGinn CJ, et al.  Radiosensitization by gemcitabine. Oncology (Huntingt). 1999;13(10 Suppl. 5):55–60
  10. Rothenberg ML, Moore MJ, Cripps MC, et al.  A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol. 1996;7(4):347–353
  11. Hui YF, Reitz J. Gemcitabine (A cytidine analogue active against solid tumors). Am J Health Syst Pharm. 1997;54(2):162–170 quiz 197–198
  12. Rockwell S, Grindey GB. Effect of 2′,2′-difluorodeoxycytidine on the viability and radiosensitivity of EMT6 cells in vitro. Oncol Res. 1992;4(4–5):151–155
  13. McGinn CJ, Shewach DS, Lawrence TS. Radiosensitizing nucleosides. J Natl Cancer Inst. 1996;88(17):1193–1203
  14. Shewach DS, Hahn TM, Chang E, et al.  Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res. 1994;54(12):3218–3223
  15. Lawrence TS, Chang EY, Hahn TM, et al.  Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′,2′-difluoro-2′-deoxycytidine (gemcitabine). Clin Cancer Res. 1997;3(5):777–782
  16. Lawrence TS, Davis MA, Hough A, et al.  The role of apoptosis in 2′,2′-difluoro-2′-deoxycytidine (gemcitabine)-mediated radiosensitization. Clin Cancer Res. 2001;7(2):314–319
  17. Extermann M, Vogt N, Forni M, et al.  Radiation recall in a patient with breast cancer treated for tuberculosis. Eur J Clin Pharmacol. 1995;48(1):77–78
  18. Bostrom A, Sjolin-Forsberg G, Wilking N, et al.  Radiation recall—another call with tamoxifen. Acta Oncol. 1999;38(7):955–959
  19. Del Guidice SM, Gerstley JK. Sunlight-induced radiation recall. Int J Dermatol. 1988;27(6):415–416
  20. Eifel PJ, McClure S. Severe chemotherapy-induced recall of radiation mucositis in a patient with non-Hodgkin’s lymphoma of Waldeyer’s ring. Int J Radiat Oncol Biol Phys. 1989;17(4):907–908
  21. Stein RS. Radiation-recall enteritis after actinomycin-D and adriamycin therapy. South Med J. 1978;71(8):960–961
  22. Greco FA, Brereton HD, Kent H, et al.  Adriamycin and enhanced radiation reaction in normal esophagus and skin. Ann Intern Med. 1976;85(3):294–298
  23. Nemechek PM, Corder MC. Radiation recall associated with vinblastine in a patient treated for Kaposi sarcoma related to acquired immune deficiency syndrome. Cancer. 1992;70(6):1605–1606
  24. Perez EA, Campbell DL, Ryu JK. Radiation recall dermatitis induced by edatrexate in a patient with breast cancer. Cancer Invest. 1995;13(6):604–607
  25. McCarty MJ, Peake MF, Lillis P, et al.  Paclitaxel-induced radiation recall dermatitis. Med Pediatr Oncol. 1996;27(3):185–186
  26. Parry BR. Radiation recall induced by tamoxifen. Lancet. 1992;340(8810):49
  27. Williams BJ, Roth DJ, Callen JP. Ultraviolet recall associated with etoposide and cyclophosphamide therapy. Clin Exp Dermatol. 1993;18(5):452–453
  28. Burdon J, Bell R, Sullivan J, et al.  Adriamycin-induced recall phenomenon 15 years after radiotherapy. JAMA. 1978;239(10):931
  29. Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol. 1999;40(3):367–398 quiz 399–400
  30. Kitani H, Kosaka T, Fujihara T, et al.  The “recall effect” in radiotherapy (Is subeffective, reparable damage involved?). Int J Radiat Oncol Biol Phys. 1990;18(3):689–695
  31. Seymour CB, Mothersill C, Alper T. High yields of lethal mutations in somatic mammalian cells that survive ionizing radiation. Int J Radiat Biol Relat Stud Phys Chem Med. 1986;50(1):167–179
  32. Parsons JT, Bova FJ, Mendenhall WM, et al.  Response of the normal eye to high dose radiotherapy. Oncology (Huntingt). 1996;10(6):837–847 discussion 847–848, 851–852
  33. Harris JR, Levene MB. Visual complications following irradiation for pituitary adenomas and craniopharyngiomas. Radiology. 1976;120(1):167–171
  34. Emami B, Lyman J, Brown A, et al.  Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21(1):109–122
  35. Debus J, Hug EB, Liebsch NJ, et al.  Brainstem tolerance to conformal radiotherapy of skull base tumors. Int J Radiat Oncol Biol Phys. 1997;39(5):967–975
  36. Yeo W, Leung SF, Johnson PJ. Radiation-recall dermatitis with docetaxel (Establishment of a requisite radiation threshold). Eur J Cancer. 1997;33(4):698–699
  37. Bokemeyer C, Lampe C, Heneka M, et al.  Paclitaxel-induced radiation recall dermatitis. Ann Oncol. 1996;7(7):755–756
  38. Raghavan VT, Bloomer WD, Merkel DE. Taxol and radiation recall dermatitis. Lancet. 1993;341(8856):1354
  39. Shenkier T, Gelmon K. Paclitaxel and radiation-recall dermatitis. J Clin Oncol. 1994;12(2):439
  40. Phillips KA, Urch M, Bishop JF. Radiation-recall dermatitis in a patient treated with paclitaxel. J Clin Oncol. 1995;13(1):305
  41. Zulian GB, Aapro MS. Docetaxel and radiation-recall severe mucositis. Ann Oncol. 1994;5(10):964
  42. Wallenborn PA, Postma DS. Radiation recall supraglottitis. A hazard in head and neck chemotherapy. Arch Otolaryngol. 1984;110(9):614–617
  43. Gabel C, Eifel PJ, Tornos C, et al.  Radiation recall reaction to idarubicin resulting in vaginal necrosis. Gynecol Oncol. 1995;57(2):266–269
  44. Stelzer KJ, Griffin TW, Koh WJ. Radiation recall skin toxicity with bleomycin in a patient with Kaposi sarcoma related to acquired immune deficiency syndrome. Cancer. 1993;71(4):1322–1325
  45. Fontana JA. Radiation recall associated with VP-16-213 therapy. Cancer Treat Rep. 1979;63(2):224–225
  46. Kharfan Dabaja MA, Morgensztern D, Markoe AM, et al.  Radiation recall dermatitis induced by methotrexate in a patient with Hodgkin’s disease. Am J Clin Oncol. 2000;23(5):531–533
  47. Jolivet J, Landry L, Pinard MF, et al.  A phase I study of trimetrexate, an analog of methotrexate, administered monthly in the form of nine consecutive daily bolus injections. Cancer Chemother Pharmacol. 1987;20(2):169–172
  48. Donaldson SS, Glick JM, Wilbur JR. Letter (Adriamycin activating a recall phenomenon after radiation therapy). Ann Intern Med. 1974;81(3):407–408
  49. Showel J, Hoover SV, Deutsch S. Radiation-recall. Int J Radiat Oncol Biol Phys. 1993;25(5):929
  50. Cassady JR, Richter MP, Piro AJ, et al.  Radiation-adriamycin interactions (Preliminary clinical observations). Cancer. 1975;36(3):946–949
  51. Ma LD, Taylor GA, Wharam MD, et al.  “Recall” pneumonitis (Adriamycin potentiation of radiation pneumonitis in two children). Radiology. 1993;187(2):465–467
  52. Kellie SJ, Plowman PN, Malpas JS. Radiation recall and radiosensitization with alkylating agents. Lancet. 1987;1(8542):1149–1150

PII: S0360-3016(02)02773-6

International Journal of Radiation Oncology * Biology * Physics
Volume 53, Issue 2 , Pages 394-400 , 1 June 2002

Article Tools

* Image Usage & Resolution